Response to letter to the editor by Leder et al. regarding commentary “Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics”
Keywords: Osteoporosis; Parathyroid hormone; Teriparatide; Denosumab; Concurrent therapy;